A common outcome measure for DMT clinical trials is the Clinical Dementia Rating scale (CDR®), a global scale to determine the presence or absence of dementia and, when present, its severity. 11 , 12 It assesses the influence of cognitive loss in six domains: three cognitive (Memory, Orientation, Judgment + Problem Solving) and three functional (Community Affairs, Home + Hobbies, Personal Care). Each of the six CDR domains are rated as unimpaired (0) or very mildly, mildly, moderately, or severely impaired (0.5, 1, 2, and 3, respectively). Summing the scores of the individual CDR domains or “boxes” yields the CDR‐SB as a continuous measure, with scores ranging from 0 (no impairment in any domain) to 18 (severe impairment in all domains). A global CDR score is then derived from the individual domain box scores. 12 Individuals with a global CDR score of 0 are cognitively unimpaired, whereas individuals with a global CDR of 0.5 are very mildly impaired and those with global scores of 1, 2, and 3 are mildly, moderately, and severely impaired, respectively.
